X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


PreviousEntry : {A96D249E-58EB-4ED5-A06D-F01B76FA7A27} | Display Title : Challenges with bisphosphonates adversely interacting with glass container systems?
NextEntry : {F8778A54-C18F-4402-B7A1-31EC780456FD} | Display Title : Challenges with bisphosphonates adversely interacting with glass container systems?
Sources

[1] Dawn M. Ecker, Susan Dana Jones, and Howard L. Levine. The therapeutic monoclonal antibody market, MABs, Jan-Feb 2015, 7(1), 9-14 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622599/

[2] Thomas Morrow and Linda Hull Felcone. Defining the difference: What Makes Biologics Unique, Biotechnol Healthc, Sep 2004, 1(4), 24-26, 28-29 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564302/
 
[3] U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. FOOD AND DRUG ADMINISTRATION, What are “Biologics” Questions and Answers: What is a biological product? How do biological products differ from conventional drugs?, August 5, 2015 https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm133077.htm

[4] S.W. Chung, T.A. Hil-lal, Y. Byun. Strategies for non-invasive delivery of biologics, J Drug Target, 2012, 20(6), 481–501, https://www.ncbi.nlm.nih.gov/pubmed/22632037

Previous Next
Frederike Ferber

Frederike Ferber

Specialist, TCS, Commercial, EU

Subscribe to receive the latest blog post